DOCSLIB.ORG

Combined Index to USP 42 and NF 37, Volumes 1–5, Including Second Supplement

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Combined Index to USP 42 and NF 37, Volumes 1–5, Including Second Supplement Combined Index to USP 42 and NF 37 Abaca-Aceto I-1 Combined Index to USP 42 and NF 37, Volumes 1±5, including Second Supplement Page citations refer to the pages of Volumes 1, 2, 3, 4 and 5 of USP 42±NF 37 and its First and Second Supplement. This index is repeated in its entirety in each volume. 1±2430 Volume 1 2431±4680 Volume 2 4681±6046 Volume 3 6047±7104 Volume 4 7105±8582 Volume 5 8583±9055 First Supplement 9057±9678 Second Supplement Numbers in angle brackets such as 〈421〉 refer to chapter numbers in the General Chapters section. butalbital and caffeine tablets, 630 and pentazocine tablets, 3433 A and caffeine tablets, 52 and pseudoephedrine hydrochloride capsules, 42 tablets, 73 Abacavir and (salts of) chlorpheniramine, oral solution, 43 oral solution, 21 dextromethorphan, and for effervescent oral solution, 44 sulfate, 25 pseudoephedrine, capsules containing at suppositories, 44 tablets, 22 least three of the following, 53 oral suspension, 45, 8619 and lamivudine tablets, 23 and (salts of) chlorpheniramine, tablets, 47 Abiraterone dextromethorphan, and extended-release tablets, 48 acetate, 27 pseudoephedrine, oral powder and tramadol hydrochloride oral acetate tablets, 28 containing at least three of the suspension, 4415 Absolute following, 55 Acetanilide, 6070 alcohol, 6071 and (salts of) chlorpheniramine, Acetate ether, 6070 dextromethorphan, and methyl, 6116 Absorbable pseudoephedrine, oral solution Acetate buffer, 6083 dusting powder, 1538 containing at least three of the TS, 6164 gelatin film, 2045 following, 58 Acetazolamide, 75, 8621 gelatin sponge, 2045 and (salts of) chlorpheniramine, for injection, 75 surgical suture, 4148, 9261 dextromethorphan, and oral suspension, 77 Absorbent pseudoephedrine, tablets containing at tablets, 78 cotton, 6070 least three of the following, 60 Acetic acid, 5553, 6070 gauze, 2043 chlorpheniramine maleate, and ammonium acetate buffer TS, 6164 Acacia, 5551 dextromethorphan hydrobromide diluted, 5553, 6070, 6098 syrup, 5551 tablets, 62 double-normal (2 N), 6177 Acamprosate calcium, 30 and codeine phosphate capsules, 64 glacial, 78, 6070, 6107 Acarbose, 32 and codeine phosphate oral solution, 65 glacial, TS, 6164, 6168 tablets, 33 and codeine phosphate oral suspension, and hydrocortisone otic solution, 2185 Acebutolol hydrochloride, 35 66 irrigation, 79 capsules, 37 and codeine phosphate tablets, 68 metaphosphoric, TS, 6170 Acepromazine maleate, 38 dextromethorphan hydrobromide, otic solution, 79 injection, 39 doxylamine succinate, and strong, TS, 6164 tablets, 40 pseudoephedrine hydrochloride oral 1 M TS, 6164 Acesulfame potassium, 5552 solution, 69 2 M TS, 6164 Acetal, 6070 and diphenhydramine citrate tablets, 71 Acetic acid in peptides, 6669 Acetaldehyde, 6070 diphenhydramine hydrochloride, and 0.008 M Acetic acid TS, 6164 TS, 6164 pseudoephedrine hydrochloride tablets, 0.3 N Acetic acid TS, 6164 Acetaldehyde ammonia trimer trihydrate, 72 Acetic anhydride, 6070 6070 and hydrocodone bitartrate tablets, 2176 Acetohydroxamic acid, 80 Acetaminophen, 40 isometheptene mucate, and tablets, 81 aspirin and caffeine tablets, 51 dichloralphenazone capsules, 2377 Acetone, 5554, 6070 and aspirin tablets, 49 and oxycodone capsules, 3313 anhydrous, 6070 butalbital and caffeine capsules, 629 and oxycodone tablets, 3315 neutralized, 6070, 6164, 6166 I-2 Aceto-Alumi Combined Index to USP 42 and NF 37 Acetonitrile, 6070 Inhalation and nasal drug products: Alfentanil spectrophotometric, 6070 aerosols, sprays, and powdersÐ hydrochloride, 123 Acetophenone, 6070 performance quality tests 〈601〉, 6746 injection, 124 p-Acetotoluidide, 6070 Isoproterenol sulfate inhalation, 2388 Alfuzosin hydrochloride, 125 Acetylacetone, 6070 Lidocaine topical, 2568 extended-release tablets, 126 Acetyl chloride, 6070 Polymyxin B sulfate and bacitracin zinc Alginates assay 〈311〉, 6589 Acetylcholine chloride, 82, 6071 topical, 3564 Alginic acid, 5562 for ophthalmic solution, 82 Povidone±iodine topical, 3607 Alizarin complexone, 6072 Acetylcysteine, 83 Thimerosal topical, 4310 Alkaline Acetylcysteine Tolnaftate topical, 4390 cupric citrate TS, 6164 compounded solution, 84 Triamcinolone acetonide topical, 4445 cupric citrate TS 2, 6164 and isoproterenol hydrochloride inhalation cupric iodide TS, 6164 solution, 85 mercuric-potassium iodide TS, 6164 solution, 84 phosphatase enzyme, 6072 N-Acetylglucosamine, 4701 Agar, 5557, 6071 picrate TS, 6164 2-Acetylresorcinol, 8882 Agarose, 6071 pyrogallol TS, 6173 3-Acetylthio-2-methylpropanoic acid, 6071 Air, medical, 101 sodium hydrosulfite TS, 6164 Acetyltributyl citrate, 5555 Air-helium certified standard, 6071 Alkaline borate buffer, 6083 Acetyltriethyl citrate, 5555 Alanine, 102, 4704 Alkaline cupric tartrate TS, 6164 N-Acetyltyrosine, 4702 L-Alanyl-L-glutamine, 4704 Alkyl (C12-15) benzoate, 5563 N-Acetyl-L-tyrosine ethyl ester, 6071 Albendazole, 103 Alkylphenoxypolyethoxyethanol, 6072 Acid oral suspension, 103 Allantoin, 131 acrylic, 6071 tablets, 104 Allopurinol, 132 alpha lipoic, 5066 Albumen TS, 6164 oral suspension, 134 dehydroacetic, 5694 Albumin tablets, 134 ferric chloride TS, 6164 bovine serum, 6071 Allyl isothiocyanate, 135 ferrous sulfate TS, 6164 human, 105 Almond oil, 5563 Folic, compounded oral soultion, 1980 rAlbumin human, 5558 Almotriptan iminodiacetic, 6111 Albuterol, 105 tablets, 138 stannous chloride TS, 6164 sulfate, 110 Almotriptan malate, 136 stannous chloride TS, stronger, 6164 tablets, 106 Aloe, 140 Acid-neutralizing capacity 〈301〉, 6588 extended-release tablets, 107 Alosetron Acidulated phosphate and sodium fluoride Alclometasone dipropionate, 111 tablets, 9094 topical solution, 4036 cream, 112 Alosetron hydrochloride, 9093 Acitretin, 86 ointment, 113 Alpha capsules, 87 Alcohol, 114, 6071 lipoic acid, 5066 Statistical tools for procedure validation 70 percent, 80 percent, and 90 percent, Alpha-chymotrypsin, 6072 〈1210〉, 7126, 7524, 7998 6071 Alpha cyclodextrin hydrate, 6072 Acrylic acid, 6071 absolute, 6071 Alpha-(2-(methylamino)ethyl)benzyl alcohol, Activated aldehyde-free, 6072 6072 alumina, 6071 alpha-(2-(methylamino)ethyl)benzyl, 6072 Alphanaphthol, 6072 charcoal, 905, 6071 amyl, 6072 Alphazurine 2G, 6158 magnesium silicate, 6071 tert-amyl, 6072, 6075, 6112 Alprazolam, 141 Acyclovir, 89 butyl, 5602 oral suspension, 142 capsules, 90 dehydrated, 116, 6072, 6093 tablets, 143 for injection, 91 dehydrated isopropyl, 6072 extended-release tablets, 145 ointment, 92 denaturated, 6072 orally disintegrating tablets, 149 oral suspension, 93 denaturated, TS, 6167 Alprenolol hydrochloride, 6072 tablets, 94 determination 〈611〉, 6776 Alprostadil, 151 Adamantane, 6071 in dextrose injection, 118 injection, 153 Adapalene, 95 diluted, 5560, 6072 Alteplase, 154 gel, 97 injection, dehydrated, 117 for injection, 157 Ademetionine disulfate tosylate, 4703 isobutyl, 6072 Alternative microbiological sampling methods Adenine, 98 isopropyl, 6072 for nonsterile inhaled and nasal products sulfate, 6071 methyl, 6072 〈610〉, 6774 Adenosine, 99 neutralized, 6072, 6121 Altretamine, 160 injection, 100 phenol TS, 6164 capsules, 161 Adipic acid, 5556, 6071 n-propyl, 6072 Alum, 6072, 6073 Admissions rubbing, 119 ammonium, 162, 6073 to NF 37, 5538, 8606, 9080 secondary butyl, 6072 potassium, 163, 6131 to USP 42, xxxi, 8598, 9072 tertiary butyl, 6072 Alumina, 6073 Alcoholic activated, 6071, 6073, 6076 ammonia TS, 6164 anhydrous, 6073 mercuric bromide TS, 6164 aspirin, codeine phosphate, and magnesia potassium hydroxide TS, 6164 tablets, 398 Aerosol potassium hydroxide TS 2, 6173 aspirin, and magnesia tablets, 391 Bacitracin and polymyxin B sulfate topical, TS, 6164 aspirin, and magnesium oxide tablets, 393 460 Alcoholic potassium hydroxide magnesia, and calcium carbonate Benzocaine, butamben, and tetracaine 0.2 N VS, 6177 chewable tablets, 167 hydrochloride topical, 506 Alcoholometric table, 6284 magnesia, calcium carbonate, and Benzocaine and menthol topical, 511 Aldehyde dehydrogenase, 6072 simethicone chewable tablets, 168 Benzocaine topical, 496 Alendronate sodium, 120 magnesia, and calcium carbonate oral Fluticasone propionate and salmeterol tablets, 121 suspension, 165 inhalation, 1960 Alfadex, 5561 magnesia, and simethicone oral Fluticasone propionate inhalation, 1943 suspension, 170 Combined Index to USP 42 and NF 37 Alumi-Ammon I-3 Alumina (continued) Amaranth, 6073 Aminosalicylate sodium, 247, 8635 magnesia, and simethicone chewable TS, 6164 tablets, 248, 8637 tablets, 172 Amcinonide, 208, 8629 Aminosalicylic acid, 250 and magnesia oral suspension, 164 cream, 209, 9096 tablets, 251, 8638 and magnesia tablets, 165 ointment, 210, 8629 3-Aminosalicylic acid, 6074 magnesium carbonate, and magnesium American ginseng, 4706 Amiodarone oxide tablets, 175 capsules, 4710 hydrochloride injection, 254, 9097 and magnesium carbonate oral suspension, extract, powdered, 4709 Amiodarone hydrochloride, 253 173 powdered, 4708 oral suspension, 256 and magnesium carbonate tablets, 174 tablets, 4713 Amiodarone hydrochloride and magnesium trisilicate oral suspension, Amifostine, 210 tablets, 9099 176 for injection, 211 Amitraz, 257 and magnesium trisilicate tablets, 177 Amikacin, 213 concentrate for dip, 258 Aluminon, 6073 sulfate, 214 Amitriptyline hydrochloride, 259 Aluminum, 6073 sulfate injection, 215 and chlordiazepoxide tablets, 919 acetate topical solution, 178 Amiloride hydrochloride, 216 and perphenazine tablets, 3460 chloride, 178 and hydrochlorothiazide tablets, 218, 8630 tablets, 261 chlorohydrate, 179 tablets, 216 Amlodipine chlorohydrate solution, 180 Amiloxate, 220 oral suspension,
Load more

Recommended publications
  • Additions and Deletions to the Drug Product List
    Prescription and Over-the-Counter Drug Product List 40TH EDITION Cumulative Supplement Number 09 : September 2020 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BUTALBITAL; CAFFEINE TABLET;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE >A> AA STRIDES PHARMA 325MG;50MG;40MG A 203647 001 Sep 21, 2020 Sep NEWA ACETAMINOPHEN; CODEINE PHOSPHATE SOLUTION;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >D> AA WOCKHARDT BIO AG 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC >A> @ 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >A> AA NOSTRUM LABS INC 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >A> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >A> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN >D> AA TEVA 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >D> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >D> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN >A> @ CEROVENE INC 325MG;5MG A 211690 001 Feb 07, 2020 Sep CAHN >A> @ 325MG;7.5MG A 211690 002 Feb 07, 2020 Sep CAHN >A> @ 325MG;10MG A 211690 003 Feb 07, 2020 Sep CAHN >D> AA VINTAGE PHARMS 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >A> @ 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >D> AA 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >A> @ 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >D> AA 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >A> @ 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >D> @ XIROMED 325MG;5MG A 211690
    [Show full text]
  • A Multifaceted Approach to Combating Leishmaniasis, a Neglected Tropical Disease
    OLD TARGETS AND NEW BEGINNINGS: A MULTIFACETED APPROACH TO COMBATING LEISHMANIASIS, A NEGLECTED TROPICAL DISEASE DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy from the Graduate School of The Ohio State University By Adam Joseph Yakovich, B.S. ***** The Ohio State University 2007 Dissertation Committee: Karl A Werbovetz, Ph.D., Advisor Approved by Pui-Kai Li, Ph.D. Werner Tjarks, Ph.D. ___________________ Ching-Shih Chen, Ph.D Advisor Graduate Program In Pharmacy ABSTRACT Leishmaniasis, a broad spectrum of disease which is caused by the protozoan parasite Leishmania , currently affects 12 million people in 88 countries worldwide. There are over 2 million of new cases of leishmaniasis occurring annually. Clinical manifestations of leishmaniasis range from potentially disfiguring cutaneous leishmaniasis to the most severe manifestation, visceral leishmaniasis, which attacks the reticuloendothelial system and has a fatality rate near 100% if left untreated. All currently available therapies all suffer from drawbacks including expense, route of administration and developing resistance. In the laboratory of Dr. Karl Werbovetz our primary goal is the identification and development of an inexpensive, orally available antileishmanial chemotherapeutic agent. Previous efforts in the lab have identified a series of dinitroaniline compounds which have promising in vitro activity in inhibiting the growth of Leishmania parasites. It has since been discovered that these compounds exert their antileishmanial effects by binding to tubulin and inhibiting polymerization. Remarkably, although mammalian and Leishmania tubulins are ~84 % identical, the dinitroaniline compounds show no effect on mammalian tubulin at concentrations greater than 10-fold the IC 50 value determined for inhibiting Leishmania tubulin ii polymerization.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • 30 Day Change Notice Effective Date
    30 Day Change Notice Effective Date: January 1st, 2021 NEW PREFERRED DRUGS THERAPEUTIC CLASS NO PA REQUIRED PREFERRED Central Nervous System (CNS) Agents: Anticonvulsants Clobazam (Generic of Onfi) Central Nervous System (CNS) Agents: Multiple Aubagio EndocrineSclerosis Agents: Osteoporosis-Bone Ossification Forteo Enhancers Gastrointestinal Agents: Anti-Emetics Bonjesta Genitourinary Agents: Benign Prostatic Hyperplasia Alfuzosin (Generic of Uroxatral) Dutasteride (Generic of Avodart) Genitourinary Agents: Electrolyte Depleter Agents Sevelamer (Generic of Renagel and Renvela) Infectious Disease Agents: Antibiotics-Macrolides Eryped Infectious Disease Agents: Antivirals-HIV Atazanavir Sulfate Oral Powder (Generic of Reyataz) Tivicay PD Infectious Disease Agents: Antibiotics-Tetracyclines Vibramycin Suspension (no PA Required for age 12 or under) Ophthalmic Agents: Antibiotics and Antibiotic -Steroid Neomycin/Polymyxin/Bacitracin/Hydrocortisone Ointment Combination Drops and Ointments Ophthalmic Agents: Glaucoma Agents Dorzolamide/Timolol (Generic of Cosopt PF) NEW CLINICAL PA REQUIRED “PREFERRED” DRUGS THERAPEUTIC CLASS CLINICAL PA REQUIRED PREFERRED Blood Formation, Coagulation, and Thrombosis Agents: Corifact Hemophilia Factors Immunomodulator Agents for Systemic Inflammatory Taltz Disease Immunomodulator Agents for Systemic Inflammatory Xeljanz 5mg Disease NEW STEP THERAPY REQUIRED “PREFERRED” THERAPEUTIC CLASS STEP THERAPY REQUIRED “PREFERRED” Central nervous System (CNS) Agents: Anti-Migraine, Aimovig Prophylaxis Treatment Ajovy
    [Show full text]
  • P2 Receptors in Cardiovascular Regulation and Disease
    Purinergic Signalling (2008) 4:1–20 DOI 10.1007/s11302-007-9078-7 REVIEW P2 receptors in cardiovascular regulation and disease David Erlinge & Geoffrey Burnstock Received: 3 May 2007 /Accepted: 22 August 2007 /Published online: 21 September 2007 # Springer Science + Business Media B.V. 2007 Abstract The role of ATP as an extracellular signalling Introduction molecule is now well established and evidence is accumulating that ATP and other nucleotides (ADP, UTP and UDP) play Ever since the first proposition of cell surface receptors for important roles in cardiovascular physiology and pathophysi- nucleotides [1, 2], it has become increasingly clear that, in ology, acting via P2X (ion channel) and P2Y (G protein- addition to functioning as an intracellular energy source, the coupled) receptors. In this article we consider the dual role of purines and pyrimidines ATP, adenosine diphosphate ATP in regulation of vascular tone, released as a cotransmitter (ADP), uridine triphosphate (UTP) and uridine diphosphate from sympathetic nerves or released in the vascular lumen in (UDP) can serve as important extracellular signalling response to changes in blood flow and hypoxia. Further, molecules [3, 4] acting on 13 P2X homo- and heteromul- purinergic long-term trophic and inflammatory signalling is timer ionotropic and 8 P2Y metabotropic receptor subtypes described in cell proliferation, differentiation, migration and [5, 6] (Table 1). To terminate signalling, ectonucleotidases death in angiogenesis, vascular remodelling, restenosis and are present in the circulation and on cell surfaces, rapidly atherosclerosis. The effects on haemostasis and cardiac degrading extracellular ATP into ADP, AMP and adenosine regulation is reviewed. The involvement of ATP in vascular [7, 8].
    [Show full text]
  • Active Pharmaceutical Ingredients
    Active Pharmaceutical Ingredients Catalog HPD-5E ® CREATING A HEALTHY WORLDTM Active Pharmaceutical Ingredients (APIs) Available for International Markets Human Pharmaceutical Department www.Pharmapex.net Catalog HPD-5E *Not all products referred to on this site are available in all countries and our products are subject to different regulatory requirements depending on the country of use. Consequently, certain sections of this site may be indicated as being intended only for users in specic countries. Some of the products may also be marketed under different trade names. You should not construe anything on this site as a promotion or solicitation for any product or for the use of any product that is not authorized by the laws and regulations of your country of residence. For inquiries about the availability of any specic product in your country, you may simply contact us at [email protected]. **Products currently covered by valid US Patents may be offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk. ©2016, Pharmapex USA, A member of Apex Group of Companies, All Rights Reserved. Toll-Free: 1.844.PHARMAPEX Fax: + 1.619.881.0035 ACTIVE PHARMACEUTICAL [email protected] CREATING A HEALTHY WORLD™ www.Pharmapex.net INGREDIENTS About Pharmapex’s Human Pharmaceuticals Department: Pharmapex’s Human Pharmaceuticals Department (HPD) is a leading source for high-quality Active Pharmaceutical Ingredients (APIs) and Finished Pharmaceutical Products (FPPs) in various markets across the globe. With an extensive product portfolio, our consortium of companies is dedicated to addressing and solving the most important medical needs of our time, including oncology (e.g., multiple myeloma and prostate cancer), neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes).
    [Show full text]
  • Supplementary Information
    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
    [Show full text]
  • 01012100 Pure-Bred Horses 0 0 0 0 0 01012900 Lives Horses, Except
    AR BR UY Mercosu PY applied NCM Description applied applied applied r Final Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 Other bovine animals for breeding,pregnant or 01022911 lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 Other buffalo for breeding, ex. pure-bred or 01023911 pregnant 2 2 2 2 0 Other buffalo for breeding, except pure-bred 01023919 breeding 2 2 2 2 4 01023990 Other buffalos 2 2 2 2 0 01029000 Other live animals of bovine species 0 0 0 0 0 01031000 Pure-bred breedig swines 0 0 0 0 0 01039100 Other live swine, weighing less than 50 kg 2 2 2 2 0 01039200 Other live swine, weighing 50 kg or more 2 2 2 2 0 01041011 Pure-bred breeding, pregnant or lactating, sheep 0 0 0 0 0 01041019 Other pure-bred breeding sheep 0 0 0 0 0 01041090 Others live sheep 2 2 2 2 0 01042010 Pure-bred breeding goats 0 0 0 0 0 01042090 Other live goats 2 2 2 2 0 Fowls spec.gallus domestic.w<=185g pure-bred 01051110 breeding 0 0 0 0 0 Oth.live fowls spec.gall.domest.weig.not more than 01051190 185g 2 2 2 2 0 01051200 Live turkeys, weighing not more than 185g 2 2
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • NON-HAZARDOUS CHEMICALS May Be Disposed of Via Sanitary Sewer Or Solid Waste
    NON-HAZARDOUS CHEMICALS May Be Disposed Of Via Sanitary Sewer or Solid Waste (+)-A-TOCOPHEROL ACID SUCCINATE (+,-)-VERAPAMIL, HYDROCHLORIDE 1-AMINOANTHRAQUINONE 1-AMINO-1-CYCLOHEXANECARBOXYLIC ACID 1-BROMOOCTADECANE 1-CARBOXYNAPHTHALENE 1-DECENE 1-HYDROXYANTHRAQUINONE 1-METHYL-4-PHENYL-1,2,5,6-TETRAHYDROPYRIDINE HYDROCHLORIDE 1-NONENE 1-TETRADECENE 1-THIO-B-D-GLUCOSE 1-TRIDECENE 1-UNDECENE 2-ACETAMIDO-1-AZIDO-1,2-DIDEOXY-B-D-GLYCOPYRANOSE 2-ACETAMIDOACRYLIC ACID 2-AMINO-4-CHLOROBENZOTHIAZOLE 2-AMINO-2-(HYDROXY METHYL)-1,3-PROPONEDIOL 2-AMINOBENZOTHIAZOLE 2-AMINOIMIDAZOLE 2-AMINO-5-METHYLBENZENESULFONIC ACID 2-AMINOPURINE 2-ANILINOETHANOL 2-BUTENE-1,4-DIOL 2-CHLOROBENZYLALCOHOL 2-DEOXYCYTIDINE 5-MONOPHOSPHATE 2-DEOXY-D-GLUCOSE 2-DEOXY-D-RIBOSE 2'-DEOXYURIDINE 2'-DEOXYURIDINE 5'-MONOPHOSPHATE 2-HYDROETHYL ACETATE 2-HYDROXY-4-(METHYLTHIO)BUTYRIC ACID 2-METHYLFLUORENE 2-METHYL-2-THIOPSEUDOUREA SULFATE 2-MORPHOLINOETHANESULFONIC ACID 2-NAPHTHOIC ACID 2-OXYGLUTARIC ACID 2-PHENYLPROPIONIC ACID 2-PYRIDINEALDOXIME METHIODIDE 2-STEP CHEMISTRY STEP 1 PART D 2-STEP CHEMISTRY STEP 2 PART A 2-THIOLHISTIDINE 2-THIOPHENECARBOXYLIC ACID 2-THIOPHENECARBOXYLIC HYDRAZIDE 3-ACETYLINDOLE 3-AMINO-1,2,4-TRIAZINE 3-AMINO-L-TYROSINE DIHYDROCHLORIDE MONOHYDRATE 3-CARBETHOXY-2-PIPERIDONE 3-CHLOROCYCLOBUTANONE SOLUTION 3-CHLORO-2-NITROBENZOIC ACID 3-(DIETHYLAMINO)-7-[[P-(DIMETHYLAMINO)PHENYL]AZO]-5-PHENAZINIUM CHLORIDE 3-HYDROXYTROSINE 1 9/26/2005 NON-HAZARDOUS CHEMICALS May Be Disposed Of Via Sanitary Sewer or Solid Waste 3-HYDROXYTYRAMINE HYDROCHLORIDE 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE
    [Show full text]